Biogen ends trial of Alzheimer’s drug.

BiogenendstrialofAlzheimersdrug
BiogenendstrialofAlzheimersdrug

March 21 (UPI) — Biotechnology giant Biogen, which was developing an Alzheimer’s disease drug with Japanese-based Eisai Co. Ltd., announced Thursday that it was ending its Phase 3 trial of the drug because it was not likely to &qout;meet their primary endpoint.&qout; The drug aducanumab was being developed a. March 21 (UPI) — Biotechnology giant Biogen, which was developing an Alzheimer’s disease drug with Japanese-based Eisai Co. Ltd., announced Thursday that it was ending its Phase 3 trial of the drug because it was not likely to “meet their primary endpoint.” The drug aducanumab was being developed as an effective treatment for those with …

This post was created with our nice and easy submission form. Create your post!

What do you think?

0 points
Upvote Downvote

Comments

avatar
  
smilegrinwinkmrgreenneutraltwistedarrowshockunamusedcooleviloopsrazzrollcryeeklolmadsadexclamationquestionideahmmbegwhewchucklesillyenvyshutmouth
Photo and Image Files
 
 
 
Audio and Video Files
 
 
 
Other File Types
 
 
 
  Subscribe  
Notify of

Loading…

0

Comments

0 comments

Posted by root